Morphic Holding, Inc. (NASDAQ:MORF) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its position in shares of Morphic Holding, Inc. (NASDAQ:MORF - Free Report) by 10.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,107,410 shares of the company's stock after purchasing an additional 200,772 shares during the quarter. Vanguard Group Inc. owned 4.24% of Morphic worth $48,281,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in Morphic by 48.5% in the third quarter. Wellington Management Group LLP now owns 3,421,820 shares of the company's stock worth $78,394,000 after purchasing an additional 1,117,985 shares during the last quarter. BlackRock Inc. increased its position in Morphic by 21.6% in the second quarter. BlackRock Inc. now owns 2,748,818 shares of the company's stock worth $157,590,000 after purchasing an additional 488,849 shares during the last quarter. State Street Corp increased its position in Morphic by 64.5% in the second quarter. State Street Corp now owns 1,975,806 shares of the company's stock worth $42,875,000 after purchasing an additional 774,789 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Morphic by 31.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,489,761 shares of the company's stock worth $56,076,000 after purchasing an additional 359,764 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in Morphic by 1,719.6% during the second quarter. Alliancebernstein L.P. now owns 1,160,617 shares of the company's stock valued at $66,538,000 after acquiring an additional 1,096,832 shares during the last quarter. Hedge funds and other institutional investors own 94.25% of the company's stock.

Morphic Stock Performance

MORF stock traded up $0.68 during mid-day trading on Tuesday, reaching $30.77. 218,861 shares of the stock traded hands, compared to its average volume of 514,100. Morphic Holding, Inc. has a one year low of $19.34 and a one year high of $63.08. The stock has a market capitalization of $1.54 billion, a PE ratio of -8.62 and a beta of 1.42. The business has a 50-day moving average price of $35.37 and a two-hundred day moving average price of $28.61.

Morphic (NASDAQ:MORF - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.05). On average, equities analysts expect that Morphic Holding, Inc. will post -3.9 earnings per share for the current fiscal year.

Insider Transactions at Morphic

In related news, CFO Marc Schegerin sold 6,041 shares of the company's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $27.49, for a total value of $166,067.09. Following the completion of the sale, the chief financial officer now directly owns 37,460 shares of the company's stock, valued at $1,029,775.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, General Counsel William Devaul sold 4,509 shares of the company's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $27.49, for a total value of $123,952.41. Following the completion of the sale, the general counsel now directly owns 23,029 shares of the company's stock, valued at $633,067.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Marc Schegerin sold 6,041 shares of the company's stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $27.49, for a total transaction of $166,067.09. Following the completion of the sale, the chief financial officer now directly owns 37,460 shares of the company's stock, valued at $1,029,775.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,876 shares of company stock worth $986,231. Insiders own 28.10% of the company's stock.

About Morphic

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.